Slowakei - Slowakisch - ŠÚKL (Štátny ústav pre kontrolu liečiv)

allergan pharmaceuticals international ltd., Írsko - multienzýmy (lipáza, proteáza a ďalšie) - 49 - digestiva, adsorbentia, acida

Slowakei - Slowakisch - ŠÚKL (Štátny ústav pre kontrolu liečiv)

medochemie ltd., cyprus - linezolid - 15 - antibiotica (proti mikrob. a vÍrusovÝm infekciam)

Slowakei - Slowakisch - ŠÚKL (Štátny ústav pre kontrolu liečiv)

medochemie ltd., cyprus - duloxetín - 30 - antidepressiva

Slowakei - Slowakisch - ŠÚKL (Štátny ústav pre kontrolu liečiv)

medochemie ltd., cyprus - duloxetín - 30 - antidepressiva

Europäische Union - Slowakisch - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - afatinib - karcinóm, pľúc bez malých buniek - antineoplastické činidlá - giotrif ako monotherapy je indikovaný na liečbu ofepidermal growth factor receptor (egfr) tki-insitného dospelých pacientov s lokálne pokročilým alebo metastatickým non-small cell lung cancer (nsclc) s aktiváciou egfr mutácií(s);lokálne pokročilým alebo metastatickým nsclc z karcinómom histology pokračuje na alebo po platinum-založené chemoterapia.

Europäische Union - Slowakisch - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Europäische Union - Slowakisch - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - empagliflozin - diabetes mellitus, type 2; heart failure; renal insufficiency, chronic - lieky používané pri cukrovke - type 2 diabetes mellitusjardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesfor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 a 5. of the annex. heart failurejardiance is indicated in adults for the treatment of symptomatic chronic heart failure.  chronic kidney diseasejardiance is indicated in adults for the treatment of chronic kidney disease.

Europäische Union - Slowakisch - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - linagliptin, metformín - diabetes mellitus, typ 2 - lieky používané pri cukrovke - liečba dospelých pacientov s typu 2 diabetes mellitus:jentadueto je uvedené ako doplnok stravy a cvičenia na zlepšenie glykemický kontroly u dospelých pacientov nedostatočne kontrolované na ich maximálna tolerovaná dávka metformín sám, alebo tí, ktorí už liečená kombinácia linagliptin a metformínom. jentadueto je indikovaný v kombinácii s sulfonylmocoviny i. triple kombinovaná liečba) ako doplnok stravy a cvičenia dospelých pacientov nedostatočne kontrolované na ich maximálna tolerovaná dávka metformín a sulfonylmocoviny.

Europäische Union - Slowakisch - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - tenektepláza - infarkt myokardu - antitrombotické činidlá - metalyse je indikovaný na trombolytickú liečbu pri podozrení na infarkt myokardu s eleváciou st alebo nedávne vľavo-blok ramienka do šiestich hodín po nástupe príznakov akútneho infarktu myokardu.

Europäische Union - Slowakisch - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - agalsidáza alfa - fabryho choroba - iné alimentárny trakt a metabolizmus výrobky, - replagal je indikovaný pre dlhodobú enzým-substitučnú liečbu u pacientov s potvrdenou diagnózou fabryho choroby (deficit α-galaktozidázy a).